This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q05.7 (Lumbar spina bifida without hydrocephalus) | Special Copayment Reduction: V179 (rare disease) |
| B. Synonyms | Lumbosacral spina bifida NOS, lumbar spina bifida without hydrocephalus |
| C. Adult onset | Likelihood of first onset in adulthood very low — spina bifida is a congenital malformation arising from an embryonic neural tube defect and is mostly diagnosed at birth or in the neonatal period. First diagnosis in adulthood is rarely possible for mild lesions without hydrocephalus, but clinically meaningful new onset is extremely exceptional. |
| 1. History | Lumbar spina bifida has been observed even in ancient Egyptian mummies, and surgical closure and nerve-preserving treatment have developed since the 19th century. |
| 2. Causes | Folic acid deficiency in early pregnancy, exposure to certain antiepileptic drugs, maternal diabetes, and genetic susceptibility (MTHFR polymorphisms, etc.) are the main risk factors. |
| 3. Genetics | Mostly multifactorial inheritance. Associated with MTHFR C677T, PAX3, and VANGL1/2 variants. Monozygotic twin concordance 50~70%. |
| 4. General epidemiology | Overall incidence of spina bifida 0.3~1.0 per 1,000 births. About 70% reduction after folic acid fortification policies. In Korea, estimated at about 0.1~0.3/1,000 relative to annual births. |
| 5. Pathophysiology | Failure of posterior neural tube closure around week 4 of gestation → dorsal lumbar neural tube defect → exposure of the spinal cord and nerve roots/cyst formation. Absence of hydrocephalus means hindbrain herniation (Chiari II) is mild or absent. |
| 6. Symptoms | Lower limb weakness and paralysis, bladder and bowel dysfunction (neurogenic bladder and bowel), lower limb sensory loss, foot deformity (clubfoot), scoliosis. |
| 7. Signs | Skin defects (lipoma, nevus, dermal sinus), absent lower limb reflexes, bladder distension and increased residual urine, spinal cord cyst, lipoma, and tethering on spinal MRI. |
| 8. Screening | Maternal serum AFP measurement (15~20 weeks of gestation), fetal ultrasound (detailed ultrasound at 18~22 weeks of gestation), amniotic fluid AFP/AChE testing, tracking of AFP changes before and after folic acid supplementation in pregnant women. |
| 9. Diagnosis | Prenatal: ultrasound + MRI (assessment of fetal spinal and cranial structures). After birth: physical examination, spinal MRI, cranial ultrasound/CT/MRI, urodynamic studies, electromyography. |
| 10. Treatment | Surgical closure of the spinal cord cyst within 24~72 hours after birth. Urologic: clean intermittent self-catheterization, anticholinergics. Orthopedic: clubfoot correction, orthoses. Multidisciplinary rehabilitation. |
| 11. Prognosis | Lumbar lesions without hydrocephalus preserve upper limb and cognitive function. Ambulation achieved in 50~80% (depending on lesion level and extent). Long-term management of neurogenic bladder required. Life expectancy relatively favorable. |
| 12. Prevention | Folic acid 400~800 μg/day before and in early pregnancy. High-dose folic acid (5 mg) prescribed for patients taking antiepileptic drugs. Strengthened prenatal screening. Genetic counseling when there is a family history. |
| 13. References | Adzick NS et al. NEJM 2011 (MOMS trial); Mitchell LE et al. Am J Med Genet C 2004 and 8 others |
The first description of spina bifida is found in ancient Egyptian medical documents from the 2nd century BC. In 1641, the Dutch anatomist Nicolaas Tulp left a detailed clinical description of myelomeningocele, which is regarded as the first systematic record of spina bifida in Western medicine. Before the 19th century, most patients with myelomeningocele died within days to weeks after birth, and leaving the lesion untreated was common.
With the development of neurosurgery in the early 20th century, surgical closure of the spinal cord cyst was introduced. In 1959, the Sheffield group in the United Kingdom pioneered systematic neonatal surgical closure and a multidisciplinary approach, and thereafter, with the standardization of meningocele closure, ventriculoperitoneal shunting (VP shunt), and urodynamic management, patient survival improved dramatically. Since the 1980s, the spread of fetal MRI and detailed ultrasound has made prenatal diagnosis possible. The US multicenter randomized controlled trial published in 2011 (MOMS trial, Management of Myelomeningocele Study) demonstrated that fetal intrauterine spinal closure significantly improved the need for ventriculoperitoneal shunting and lower limb functional outcomes compared with postnatal closure, shifting the paradigm of spina bifida treatment toward prenatal intervention.
Lumbar spina bifida is the most common location among spina bifida cases and includes spinal cord defects occurring at the level of the 1st~5th lumbar vertebrae (L1-L5). Lumbar spina bifida without hydrocephalus has mild or no Chiari II malformation and is not accompanied by ventricular enlargement, so upper limb and cognitive function are relatively preserved. Since the mid-1990s, when folic acid fortification programs were introduced worldwide, the overall incidence of spina bifida has declined greatly, and in Korea, too, the incidence has been declining since the 2000s with folic acid supplementation campaigns for pregnant women and improved prenatal screening. Recently, minimally invasive fetal endoscopic closure, stem cell therapy research, and reconstruction techniques using 3D bioprinting are under research and development.
The history of spina bifida is also a case that highlighted not only advances in treatment technology but also the importance of preventive medicine. In 1991, a randomized controlled trial by the UK Medical Research Council reported that folic acid supplementation reduced the risk of recurrence by 72%, prompting countries around the world to formalize folic acid recommendations for before and in early pregnancy. The United States has implemented a grain fortification program since 1998, lowering the incidence of spina bifida by about 35%. In this way, the history of spina bifida is also a history of a multidisciplinary approach in which neurosurgery, urology, rehabilitation medicine, obstetrics and gynecology, and genetics cooperate.
Lumbar spina bifida without hydrocephalus is a congenital neural tube defect (NTD) that occurs when posterior closure of the embryonic neural tube is not completed around day 28 of gestation (4 weeks of pregnancy, 6 weeks from the last menstrual period). In normal development, both sides of the neural plate fold to form the neural tube, which then closes sequentially in the cranial-to-caudal direction; failure of closure at the lumbar level causes lumbar spina bifida.
Folic acid deficiency is the best-established causal factor. Folic acid is a water-soluble vitamin essential for one-carbon metabolism, which is required for cell division and DNA synthesis, and its deficiency impairs the closure process of rapidly dividing neural tube cells. The risk of spina bifida is elevated in pregnant women with the C677T and A1298C polymorphisms of MTHFR (methylenetetrahydrofolate reductase), an enzyme gene involved in folate metabolism. Adequate folic acid supplementation from 1 month before pregnancy through the 3rd month of pregnancy can reduce the risk of spina bifida by 50~70%.
Exposure to antiepileptic drugs (AED) is an important environmental cause. Valproic acid interferes with folate metabolism and inhibits inositol signaling required for neural tube closure, raising the risk of spina bifida to about 1~2%. Carbamazepine also slightly increases the risk. In addition, maternal diabetes (pregestational diabetes, poor glycemic control), obesity, excessive body heat (hyperthermia, high fever in early pregnancy), and exposure to certain retinoids and methotrexate have also been reported as risk factors.
Genetic factors: spina bifida is a multifactorial genetic disease, and when there is a family history, the recurrence risk rises to about 4~8% compared with the general population. In subsequent pregnancies of parents who have previously had an affected child, the recurrence rate is about 3~5%. Variants in planar cell polarity (PCP) pathway genes such as VANGL1, VANGL2, CELSR1, and SCRIB, and in the PAX3, ZIC2, and T (brachyury) genes have been reported to be associated with the development of spina bifida. It may also occur together with some chromosomal abnormalities (trisomy 18, 13).
Particular features of lumbar spina bifida: among all spina bifida, the lumbar level is the most common (about 40~50%), and when the lumbosacral (L4-S1) level is included, the degree of lower limb paralysis and the severity of bladder and bowel dysfunction differ. Absence of hydrocephalus means that Chiari II malformation is absent or mild, corresponding to a more favorable subtype without complications of increased intracranial pressure due to ventricular enlargement.
The genetic architecture of neural tube defects (NTD), including lumbar spina bifida, follows a complex multifactorial mode of inheritance. Cases caused by a single gene defect are few; most are complex genetic diseases in which multiple genetic variants and environmental factors (folic acid deficiency, diabetes, hyperthermia, etc.) interact. The concordance rate in monozygotic twins is about 50~70%, showing that both genetic background and environmental factors contribute to development.
MTHFR gene: the C677T (rs1801133) and A1298C (rs1801131) polymorphisms of MTHFR, which encodes methylenetetrahydrofolate reductase, the key enzyme of folate metabolism, are the genetic variants most strongly associated with NTD. C677T homozygosity (TT type) reduces enzyme activity by about 70%, raising blood homocysteine and impairing folate metabolism. In meta-analyses, the TT type increases NTD risk about 1.5~2-fold. However, the increase in risk from MTHFR variants alone is not large, and adequate folic acid supplementation can offset the risk in this genotype.
Planar cell polarity (PCP) pathway genes: neural tube closure depends on convergent extension movements of neuroepithelial cells, and PCP signaling plays a key role in this process. Many variants of the VANGL1, VANGL2, CELSR1, SCRIB, and PRICKLE genes have been reported in human NTD patients. In loss-of-function mouse models of these genes, neural tube defects including craniorachischisis are reproduced. Clinically, the penetrance of these gene variants is incomplete, so only some members of carrier families are affected.
Other related genes: the transcription factor PAX3 (the Waardenburg syndrome gene) is involved in neural crest cell development and neural tube formation, and some studies have reported an association with NTD. The ZIC2 and ZIC3 genes are associated with forebrain defects and neural tube defects. Autoantibodies to the folate receptor alpha (FOLR1) have been found in the mothers of some NTD patients, raising the possibility that an autoimmune mechanism interferes with folate transport. Copy number variants (CNV), including chromosomal microdeletions and duplications, are also being studied for association with NTD.
Genetic counseling: siblings of patients with spina bifida have a recurrence risk about 3~5% higher than the general population, and when one parent is affected, the risk for children is about 4~8%. When there is already an affected child, the recurrence risk in the next pregnancy is about 3~5%, and the risk rises further if there are two affected children. In such cases, consultation with a genetic counselor, high-dose folic acid (5 mg/day) supplementation, and prenatal diagnosis through detailed prenatal ultrasound and MRI and amniotic fluid AFP/AChE testing are recommended. NTD-related gene panel testing based on whole exome/genome analysis (WES/WGS) is performed for research and clinical purposes at some specialized institutions.
Neural tube defects (NTD) are the most common type of congenital central nervous system malformation, occurring at a frequency of about 0.5~2.0 per 1,000 births worldwide. Spina bifida is the form of NTD that involves only the spinal cord without a brain defect and accounts for about 40~50% of all NTD. Lumbar spina bifida is the most common location among all spina bifida, accounting for about 40~50% of all spina bifida. Lumbar spina bifida without hydrocephalus (Q05.7) is the subtype among these that is not accompanied by Chiari II malformation and hydrocephalus.
Changes in incidence by region and period are marked. Before the implementation of folic acid fortification policies, the incidence of spina bifida in the United States was about 0.5 per 1,000 births, and after the introduction of grain folic acid fortification in 1998 it decreased by about 23~35%. Countries that implemented national fortification policies, such as the United Kingdom, Canada, and Chile, have reported similar decreases. Ireland and some regions of the United Kingdom have historically had high incidence (3~5 per 1,000 births), while East Asian countries are relatively low.
Epidemiology in Korea: according to data from the Health Insurance Review & Assessment Service (HIRA) and Statistics Korea, the annual birth incidence of spina bifida (all Q05 codes) in Korea since the 2000s is estimated at about 1.0~2.5 per 10,000 births. The incidence has decreased with folic acid supplementation campaigns (after the official recommendation of the Ministry of Health and Welfare (MOHW) in the early 2000s) and improved prenatal screening, but because fortified food policies have not been implemented to the level of the United States and Canada, there is reported room for further reduction. Among lumbar spina bifida, the subtype without hydrocephalus (Q05.7) accounts for a smaller proportion than the subtypes with hydrocephalus (Q05.1, Q05.2, etc.) among all spina bifida and shows a relatively mild clinical course. It tends to occur at a slightly higher frequency in boys than in girls, but in some countries the sex difference is not clear.
Socioeconomic and geographic factors also affect incidence. Incidence is high in low-income groups, nutritionally deficient regions, and populations with limited access to folic acid-fortified foods. Ethnically, a somewhat higher incidence has been reported in Hispanic populations, and it is relatively low in East Asian populations. When prenatal ultrasound screening leads to intrauterine death or a decision to terminate the pregnancy for fetuses with severe spina bifida, the prevalence at birth is counted lower than the actual incidence. Therefore, fetal data must be included to determine the actual incidence.
The pathogenesis of lumbar spina bifida begins with failure of posterior neural tube closure, which occurs around day 28~30 of embryonic development (post-fertilization). In normal neural tube formation (primary neurulation), the lateral parts of the neural plate elevate to form neural folds, and when these meet and fuse in the dorsal midline, the neural tube is completed. When a defect occurs in this closure process at the lumbosacral level, the posterior vertebral arch and the spinal cord and meninges are left unclosed.
Pathoanatomically, spina bifida is a spectrum disorder. In the most severe form, myelomeningocele, the spinal cord and meninges protrude outside the skin to form a cyst, and the exposed spinal cord is directly exposed to cerebrospinal fluid, air, and infectious agents. In meningocele, only the meninges protrude and the spinal cord remains in place, so neurological damage is less. In spina bifida occulta, only the vertebral arch is defective, without herniation of the meninges or spinal cord, so only skin lesions (dermal sinus, lipoma, hair tuft, dimple) appear externally.
Specific pathogenesis of lumbar spina bifida without hydrocephalus: in typical myelomeningocele, Chiari malformation type II develops, in which the cerebellar tonsils and brainstem descend through the foramen magnum into the spinal canal, causing impaired cerebrospinal fluid circulation → hydrocephalus. In Q05.7 (lumbar lesion without hydrocephalus), Chiari II malformation is mild or absent and cerebrospinal fluid circulation is maintained, so ventricular enlargement does not occur. This is understood to be because posterior fossa fluid dynamics differ depending on lesion size, location, and degree of spinal cord herniation.
Dual mechanism of neural injury (two-hit hypothesis): the primary injury is the congenital abnormal differentiation of the spinal cord itself, and the secondary injury is progressive neural destruction of the exposed spinal cord by mechanical trauma, toxic substances in the amniotic fluid, and infection. This "two-hit" hypothesis provides the theoretical basis for the idea that fetal intrauterine spinal closure blocks the secondary injury and preserves neural function. The results of the MOMS trial, which reported improved lower limb function after intrauterine closure, support this hypothesis.
Mechanism of bladder and bowel dysfunction: the lumbar spinal cord (L1~S3) contains the autonomic and somatic control centers of the lower urinary tract and rectum. When the spinal cord and nerve roots at this level are damaged in lumbar spina bifida, coordination between the bladder detrusor muscle and the external urethral sphincter is lost, resulting in neurogenic bladder. Detrusor-sphincter dyssynergia can progress from increased bladder pressure → upper urinary tract damage → renal failure, so early urologic management is decisive for prognosis.
The clinical symptoms of patients with lumbar spina bifida without hydrocephalus vary depending on the level of the spinal cord lesion (upper lumbar L1~L3 vs. lower lumbar L4~L5 and the sacral junction), its extent, and the degree of neural damage. Because there is no hydrocephalus, there are no symptoms of increased intracranial pressure (headache, vomiting, reduced vision, altered consciousness), but dysfunction of the lower limbs and pelvic organs due to spinal cord and nerve root damage is the main clinical problem.
Motor dysfunction: lower limb weakness or paralysis is characteristic. With upper lumbar lesions (L1-L2), the hip flexors are preserved, but knee extension, ankle dorsiflexion and plantarflexion, and toe movement are lost. At the L3 level, knee extension is partly possible, and at L4 ankle dorsiflexion becomes possible. With L5-level lesions, partial preservation of ankle and toe movement often allows independent walking with orthoses. Because of lower limb muscle imbalance, equinovarus deformity (clubfoot) commonly accompanies it.
Sensory impairment: touch, pain, temperature sensation, and proprioception are lost in the dermatomes below the lesion level. Areas of sensory loss are the main risk sites for pressure ulcers, which develop especially at the heels, sacrum, and ischial tuberosities. Because patients do not feel pain, recognition of early wounds is delayed, so periodic skin examination is essential.
Bladder dysfunction (neurogenic bladder): bladder dysfunction occurs in most patients and is one of the most important complications, directly affecting long-term preservation of renal function. Incomplete voiding, increased residual urine, urinary incontinence, and elevated bladder pressure appear. The combination of an overactive detrusor and impaired sphincter relaxation places back-pressure on the upper urinary tract, which can progress to hydronephrosis, pyelonephritis, and renal failure. Regular bladder emptying by clean intermittent catheterization (CIC) is the key to prevention.
Bowel dysfunction (neurogenic bowel): fecal incontinence or constipation occurs. Because of loss of rectal sensation, patients do not feel the urge to defecate, and reduced anal sphincter function makes voluntary bowel control difficult. A regular bowel management program (bowel training, suppositories, enemas, dietary adjustment) is important for social participation and quality of life.
Spinal and pelvic deformities: because of lumbar muscle imbalance, abnormal growth, and chronic sitting posture, skeletal deformities such as scoliosis, kyphosis, and hip dislocation develop progressively. These place additional burdens on walking ability, sitting balance, and cardiopulmonary function. Orthopedic follow-up and timely surgical intervention are important.
The physical signs of lumbar spina bifida without hydrocephalus vary with age from the neonatal period through adolescence and adulthood. The most conspicuous finding at birth is a skin defect of the lower back (lumbar level) and a cystic lesion with exposed spinal cord and meninges or a skin-covered bulge.
Skin and surface findings: in the myelomeningocele form, a cyst containing meningeal and spinal cord tissue is observed on the dorsal lumbosacral region. The lesion surface is covered with thin, fragile skin or exposes mucosal tissue, so sterile management immediately after birth is essential. In spina bifida occulta, a dermal sinus, hemangioma, hair tuft, lipoma, or sacral dimple in the lumbosacral region appears as an external sign. These skin signs suggest the presence of internal spinal cord lesions such as tethered cord.
Neurological signs: loss or reduction of deep tendon reflexes, lower limb weakness, and sensory loss below the lesion level are observed. Ankle clonus, the Babinski reflex (if accompanied by upper motor neuron damage), and loss of the anal reflex are evaluated. In newborns, absence of spontaneous lower limb movement, no response to skin pinching, and absence of foot plantarflexion are early neurological assessment indicators.
Urologic signs: continuous dribbling of urine in the neonatal period, a palpable distended bladder, and increased residual urine on bladder ultrasound appear. Urodynamic studies measure detrusor overactivity, sphincter dyssynergia, and abnormalities of bladder capacity and compliance. Over the long term, upper urinary tract damage is monitored by cystoscopy and renal function tests (GFR, renal ultrasound, renal scan).
Orthopedic signs: equinovarus foot, a hip flexion–abduction–external rotation posture, knee flexion contracture, and leg length discrepancy are identified on physical examination. With growth, scoliosis, lumbar hyperlordosis, and pelvic obliquity progress. In patients who spend long periods seated without walking, decreased bone density and increased risk of pathological fractures also occur.
Imaging findings: spinal X-rays confirm the defect of the posterior lumbar vertebral arch. Spinal MRI is the standard test for evaluating the spinal cord level, spinal cord cyst, lipoma, tethered cord, and Chiari malformation. Hydrocephalus is evaluated by cranial MRI or ultrasound, and in Q05.7 lateral ventricular enlargement is absent or mild. Renal and bladder ultrasound is used to monitor for urologic complications.
Prenatal screening for neural tube defects, including lumbar spina bifida, is carried out by a stepwise combination of maternal serum marker testing, fetal ultrasound, and amniotic fluid testing. The goal of prenatal screening is to support, through early diagnosis, planning before delivery (mode of delivery, place of delivery, care immediately after birth), decisions on fetal treatment (evaluation of eligibility for intrauterine closure), and family counseling.
Maternal serum alpha-fetoprotein (MSAFP): MSAFP, measured between 15 and 20 weeks of gestation, is the basic screening test for neural tube defects. In open spinal defects, fetal serum AFP leaks into the amniotic fluid and maternal serum, raising MSAFP to 2.5 times the normal median (MOM) or higher. Sensitivity is about 80~85% for open myelomeningocele, while in spina bifida occulta AFP is normal, making screening difficult. When MSAFP is elevated, the cause is determined by detailed fetal ultrasound.
Fetal ultrasound (detailed anatomy ultrasound): detailed anatomy ultrasound performed at 18~22 weeks of gestation is the key to prenatal diagnosis of spina bifida. On transverse views of the spine, splaying of the posterior vertebral arch (open posterior arch), skin defects, and cyst formation are identified. Among intracranial findings, the "lemon sign" (frontal bone scalloping) and the "banana sign" (cerebellar flattening) suggest accompanying Chiari II, but in Q05.7 (no hydrocephalus) these intracranial findings are absent or mild, so the ultrasound detection rate may be relatively low. Lateral ventricular measurements, cerebellar structure, and skull shape are evaluated in detail, and the lesion level and extent are measured for use in predicting prognosis.
Fetal MRI: performed as a complement when a spinal cord lesion is suspected on ultrasound, fetal MRI accurately evaluates the extent of spinal cord exposure, the degree of Chiari malformation, cerebellar displacement, and lateral ventricular size, with tissue contrast superior to ultrasound. When performed after 24 weeks of gestation, fetal anatomy is sufficiently developed for easy interpretation. Fetal MRI is also essential for evaluating eligibility for fetal spinal closure.
Amniotic fluid testing (amniotic fluid AFP and AChE): performed at 15~20 weeks of gestation when ultrasound findings are unclear or to identify the cause of MSAFP elevation. Positive acetylcholinesterase (AChE) together with elevated amniotic fluid AFP is highly specific for open neural tube defects. Fetal karyotyping (trisomy 18, 13, Down syndrome, etc.) is performed at the same time to exclude accompanying chromosomal abnormalities.
Management of carrier families and groups at risk of recurrence: in groups at risk of recurrence, such as parents who previously had an affected child and siblings or children of patients with spina bifida, intensified follow-up is recommended, including preconception genetic counseling, high-dose folic acid (5 mg/day) supplementation, nuchal translucency + fetal anatomy ultrasound at 11~14 weeks of gestation, detailed anatomy ultrasound at 18~22 weeks of gestation, and amniotic fluid testing if needed.
The diagnosis of lumbar spina bifida without hydrocephalus is divided into the prenatal and postnatal periods. Prenatally, diagnosis is made by ultrasound, MRI, and amniotic fluid testing, and after birth, the characteristics of the lesion and the degree of neural damage are accurately evaluated through various tests, including physical examination, neuroimaging, urodynamic studies, and electrophysiological studies.
Prenatal diagnosis: lumbar spina bifida without hydrocephalus is diagnosed when a lumbar vertebral arch defect, cyst formation, and skin defect are identified on detailed anatomy ultrasound (18~22 weeks of gestation) and intracranial findings (lemon sign, banana sign, ventricular enlargement) are absent or mild. Fetal MRI accurately confirms the extent of the spinal cord lesion, the presence of Chiari malformation, and ventricular size. Open lesions are confirmed by amniotic fluid AFP and AChE testing. Accompanying chromosomal abnormalities are excluded by fetal karyotyping.
Postnatal neurological evaluation: immediately after birth, a neurosurgeon evaluates the lesion size, skin integrity, and whether the spinal cord is exposed. Spontaneous lower limb movement, sensory responses, deep tendon reflexes, and the anal reflex are systematically examined to determine the level of the neurological deficit. Neurological level assessment according to the American Spinal Injury Association (ASIA) classification is used for functional prediction and rehabilitation planning.
Cranial imaging: in all newborns with spina bifida, the presence of hydrocephalus is checked by cranial ultrasound or MRI. In Q05.7, normal or mildly enlarged lateral ventricles are observed. The presence and degree of Chiari II malformation are also evaluated by MRI. Signs of increased intracranial pressure (bulging anterior fontanelle, suture diastasis, sunset eye sign) are carefully observed.
Spinal MRI: whole-body MRI (including the entire spine) evaluates the location and extent of the spinal cord lesion, tethered cord, lipoma, dermal sinus, and syringohydromyelia. In postoperative follow-up as well, spinal MRI is essential for monitoring for re-tethering.
Urodynamic studies (urodynamics): urodynamic studies are performed from the neonatal period to evaluate bladder function. Bladder capacity, bladder pressure during filling, detrusor activity, urethral sphincter activity, and bladder compliance are measured to classify the type of neurogenic bladder. Based on the results, the frequency of intermittent catheterization, anticholinergic prescription, and urologic surgical plans are established.
Electromyography and nerve conduction studies: spontaneous potentials and motor unit potentials of the lower limb muscles are evaluated to confirm the level and degree of neuromuscular damage. Somatosensory evoked potentials (SSEP) and motor evoked potentials (MEP) are used for electrophysiological evaluation of spinal cord function. Intraoperative neuromonitoring (IONM) is performed during spinal closure and tethered cord release to prevent neural injury.
Treatment of lumbar spina bifida without hydrocephalus requires a comprehensive approach involving a multidisciplinary team of neurosurgery, urology, orthopedics, pediatrics, rehabilitation medicine, developmental pediatrics, and others. Long-term, continuous management is required, from surgical care immediately after birth to rehabilitation in adulthood.
Neonatal surgical spinal closure: for open myelomeningocele (exposed spinal cord), primary surgical closure is performed within 24~72 hours after birth. By dissecting the meninges and surrounding skin to close the cyst and protect the spinal cord, the risk of infection (meningitis) is eliminated and secondary neural injury is prevented. When the skin defect is large, skin flap surgery (flap) is needed. Early closure is decisive for preventing meningitis and preserving neural function. Recently, fetal intrauterine spinal closure performed at 24~26 weeks of gestation has been introduced at some tertiary institutions in Korea and abroad, with reported reductions in the need for postnatal ventriculoperitoneal shunting and improvements in lower limb function.
Management of hydrocephalus: in Q05.7 (no hydrocephalus), shunt surgery is initially unnecessary, but because hydrocephalus may progress during growth, regular monitoring is done with cranial ultrasound and MRI. When ventricular enlargement progresses, a ventriculoperitoneal shunt (VP shunt) or endoscopic third ventriculostomy (ETV) is performed.
Urologic management: the core treatment for neurogenic bladder is clean intermittent catheterization (CIC). CIC is started within the first few weeks of life according to urodynamic results; caregivers perform it at first, and the age at which the patient performs it independently is gradually brought forward. For detrusor overactivity, anticholinergics (oxybutynin, tolterodine) are used. When intravesical pressure remains elevated with a risk of upper urinary tract damage, surgical methods such as augmentation cystoplasty, intravesical mitomycin instillation, and intravesical botulinum toxin injection are considered. Adequate fluid intake and CIC hygiene education are important for preventing urinary tract infections.
Bowel management: for combined management of constipation and fecal incontinence, a high-fiber diet, adequate fluid intake, regular suppositories/enemas, and a bowel training program are implemented. The Malone antegrade continence enema (MACE) is a method of creating a laparoscopic access route to the cecum to perform retrograde enemas, and it improves social participation in patients with difficulty controlling bowel movements.
Orthopedic treatment: clubfoot (equinovarus) treatment begins immediately after birth with the Ponseti method (serial casting), and Achilles tenotomy or tendon transfer is performed if needed. For hip dislocation or subluxation, correction of muscle imbalance (tendon transfer) and pelvic osteotomy are considered. For scoliosis, spinal fusion is performed if it progresses after bracing (orthosis). Ambulation is maximized by prescribing orthoses (lower limb orthoses, AFO, etc.).
Tethered cord release: when, with growth, the spinal cord becomes tethered by scar tissue and lower limb weakness, pain, worsening bladder function, and spinal deformity progress, surgical tethered cord release is performed. Neural injury is minimized with intraoperative neuromonitoring (IONM).
The prognosis of lumbar spina bifida without hydrocephalus (Q05.7) is generally better than that of the subtypes with hydrocephalus. Upper limb and cognitive function are mostly normal, and with appropriate multidisciplinary management, school education, social participation, and independent living are often possible. However, limitations of lower limb motor and sensory function and of bladder and bowel function are chronic issues requiring lifelong management.
Ambulatory ability: the lower the lesion level (L4-L5), the higher the likelihood of independent walking with orthoses. At or below the L4 level, about 70~80% of patients maintain community ambulation into adulthood, while at the L1-L2 level patients mainly use wheelchairs. The proportion in which ambulatory ability established in childhood is maintained in adulthood is about 50~70%, and obesity, progression of spinal deformity, and spinal cord retethering are risk factors for decline in ambulatory ability.
Urologic and renal function: preservation of renal function is key to long-term prognosis. Starting CIC and appropriate drug treatment from the neonatal period can prevent most upper urinary tract damage. Monitoring is done with regular urodynamic studies and renal ultrasound and renal function tests, and surgical intervention is needed when recurrent urinary tract infections or elevated bladder pressure persist. When urinary tract complications are appropriately managed, near-normal renal function can be maintained into adulthood.
Cognitive function and learning ability: without hydrocephalus, the intelligence quotient (IQ) is often in the normal range, and the incidence of learning disabilities is lower than in the subtypes with hydrocephalus. However, mild neurocognitive abnormalities such as attention deficit, reduced processing speed, and limited visuospatial cognition have been reported in some patients. Early educational intervention and special education support help academic achievement.
Quality of life: quality of life is significantly higher in patients capable of independent walking and those with well-managed bladder and bowel. Some patients obtain employment, live independently, marry, and become pregnant in adulthood, and psychosocial support and participation in self-help groups contribute to improved quality of life. Chronic pain, pressure ulcers, spinal deformity, and urologic problems are the main factors limiting quality of life.
Life expectancy: the life expectancy of patients with spina bifida receiving modern management has improved greatly compared with several decades ago. The life expectancy of patients with lumbar lesions without hydrocephalus is reported to be 60~70 years or more, and renal failure, recurrent urinary tract infections, infected pressure ulcers, and cardiopulmonary complications are the main causes of death. Long-term follow-up based at multidisciplinary specialty centers is essential for improving life expectancy.
Prevention of lumbar spina bifida consists of a stepwise strategy of primary (preventing occurrence), secondary (early diagnosis and fetal intervention), and tertiary (preventing complications and maintaining function) prevention.
Primary prevention — folic acid supplementation: all women who may become pregnant, especially those planning pregnancy, take folic acid 400~800 μg/day from at least 1 month before pregnancy through the 3rd month of pregnancy. In high-risk groups—history of a previous affected child, family history of spina bifida, use of antiepileptic drugs (valproic acid, carbamazepine), maternal diabetes, obesity—high-dose folic acid 5 mg/day is recommended. In Korea, under the Mother and Child Health Act, public health centers distribute folic acid supplements to pregnant women free of charge, and continued expansion of this program is recommended. The population-wide preventive effect of introducing a folic acid-fortified food policy also needs to be reviewed.
Primary prevention — risk factor management: pregnant women with diabetes should strictly control blood glucose from before pregnancy, keeping HbA1c below 6.5%. Patients with epilepsy who definitely need valproic acid should take high-dose folic acid supplementation and discuss with a neurologist before pregnancy the possibility of changing medication. High fever in early pregnancy (4~6 weeks) is treated immediately with antipyretic measures, and saunas and hot baths are avoided in early pregnancy. In women taking antiepileptic drugs, switching to drugs such as lamotrigine or levetiracetam is considered where possible.
Secondary prevention — prenatal screening: MSAFP testing at 15~20 weeks of gestation and detailed anatomy ultrasound at 18~22 weeks of gestation are included in standard prenatal care. When abnormal findings are present, confirmation is made by fetal MRI and amniotic fluid AFP/AChE testing. In high-risk groups, careful spinal evaluation is recommended even on nuchal translucency ultrasound at 11~14 weeks of gestation. When the eligibility criteria for fetal intrauterine spinal closure are met (19~25 weeks of gestation, singleton pregnancy, L1-S1 level, accompanying Chiari II malformation, no severe fetal anomalies, etc.), prompt referral to a specialized center is made.
Tertiary prevention — prevention of complications: from the neonatal period after birth, registration with a specialized spina bifida clinic involving a multidisciplinary team and regular follow-up are begun. Upper urinary tract damage is prevented by early management of neurogenic bladder (starting CIC, use of anticholinergics). Early detection of signs of tethered cord and release surgery, timely correction of orthopedic deformities, and pressure ulcer prevention education are key. Nutritional management to prevent overweight and obesity and encouragement of feasible physical activity such as swimming and upper limb exercise contribute to long-term health maintenance.